Ekso Bionics Holdings, Inc. (EKSO)
Valuation Overview•Is Ekso Bionics Holdings, Inc. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 31/100; weak margins or elevated debt leverage warrant caution.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. However, capital return yields remain modest, anchored by a strong, well-covered dividend yield.
EKSO struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is facing top-line contraction (-0.3% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-134.1%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $2.1M | -28.6% | -0.3% | +7.6% | +4.0% | |
| EBITDA | -$5.6M | — | +7.1% | — | — | |
| Net Income | -$6.9M | -3.2% | +8.1% | — | +5.0% | |
| EPS (Diluted) | $-2.04 | -776.8% | — | — | +10.9% | |
| Free Cash Flow | -$2.1M | -21.3% | +7.0% | -6.5% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 52.9% | 52.1% | 52.9% | 45.7% |
| Operating Margin | -134.1% | -81.7% | -97.7% | -161.5% |
| Net Margin | -135.7% | -79.2% | -88.3% | -150.6% |
| FCF Margin | -103.4% | -71.9% | -86.1% | -145.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q1'26Latest | $-0.08 | $-1.56 | -1850.0% | ||
| Q4'25 | $-0.99 | $-0.54 | +45.5% | ||
| Q3'25 | $-1.20 | $-1.24 | -3.3% | ||
| Q2'25 | $-1.65 | $-1.80 | -9.1% | ||
| Q1'25 | $-0.07 | $-0.14 | -100.0% | ||
| Q4'24 | $-0.08 | $-0.10 | -25.0% | ||
| Q3'24 | $-0.11 | $-0.13 | -18.2% | ||
| Q2'24 | $-0.16 | $-0.20 | -25.0% |
Total return is +553.2% (1Y), outperforming the benchmark by +528.2%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +199.1% | +189.8% | — |
| 1Y | +553.2% | +528.2% | — |
| 3YCAGR | +9.2% | -14.9% | — |
| 5YCAGR | -22.0% | -36.7% | — |
| 10YCAGR | -32.5% | -47.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about EKSO (EKSO) valuation, health, and returns.
EKSO valuation is being assessed using available models.
EKSO has multiple valuation anchors: Wall Street Analyst Target: $6.00 (implying -74.4% upside). A convergence of these signals offers higher conviction.
EKSO displays weak financial health with a composite quality score of 31/100, supported by a Altman Z-Score of -16.6 (distress zone), Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of -88.1%.
EKSO pays a 0.4% dividend yield, covered by a 0% payout ratio with 0 years of growth, supplemented by a 0.0% buyback yield.
EKSO's current growth trajectory is Decelerating. The company achieved -28.6% 1Y revenue growth and -776.8% 1Y EPS growth, compared to its 3Y revenue CAGR of -0.3%.
Wall Street consensus is Buy based on 4 analysts, beating EPS expectations in 17% of recent quarters with a -1-quarter streak. The consensus price target represents a -74.4% change from current levels.
Investment risks for EKSO include: -38.2% 1-year max drawdown, high beta (3.15x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 3.15x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.